$ARIA Recent Headlines Six stocks to watch 4:27 p.m. Feb.

New Post Public Reply Private Reply Replies (0) Message Board

Mar 18, 2014 at 11:26 AM

$ARIA Recent Headlines

Six stocks to watch 4:27 p.m. Feb. 26, 2014 - The Trading Deck
6 stocks to watch 4:34 p.m. Feb. 12, 2014 - The Trading Deck
Ariad falls after wild ride upward, while Care.com holds on to its gains 10:02 p.m. Jan. 27, 2014 - Russ Britt
Apple green ahead of earnings; Caterpillar tops gainers 4:42 p.m. Jan. 27, 2014 - Sue Chang
Ariad shares jump nearly 30% on rumors of Big Pharma takeover 2:43 p.m. Jan. 24, 2014 - Russ Britt
5 charts to watch 4:52 p.m. Jan. 15, 2014 - The Trading Deck
Apple closes lower; B. of A. rises on analyst call 5:15 p.m. Jan. 2, 2014 - Wallace Witkowski
Apple gains on China Mobile deal; homebuilders rally 4:33 p.m. Dec. 23, 2013 - Wallace Witkowski
Suspension is lifted for Ariad's leukemia drug 7:33 a.m. Dec. 23, 2013 - MarketWatch.com
J.C. Penney and more of the year's most profitable shorts 4:23 p.m. Dec. 9, 2013 - blogs.marketwatch.com
Hewlett-Packard, a cyclical green light and why silver is in trouble 9:50 a.m. Nov. 26, 2013 - Shawn Langlois
Ariad takes another pounding after leukemia treatment is pulled 1:14 p.m. Oct. 31, 2013 - Russ Britt
H-P has best day in four months on upbeat outlook 4:34 p.m. Oct. 9, 2013 - Sue Chang
Ariad plummets 70% after drug test patients have serious clotting issues 11:38 a.m. Oct. 9, 2013 - Russ Britt
FDA places partial hold on Ariad's Iclusig trials 8:16 a.m. Oct. 9, 2013 - MarketWatch.com
Dan Loeb makes bet on Disney 8:06 p.m. Aug. 14, 2013 - David Benoit
Onyx share surge lifts several boats in biotech harbor, including ETFs 11:33 a.m. July 1, 2013 - Russ Britt
SAC Capital Advisors likes this pharma stock 4:24 p.m. April 18, 2013 - Insider Monkey
Ariad Pharma up 6% to $20.09 11:35 a.m. Dec. 17, 2012 - Steve Gelsi
FDA OKs Iclusig to treat rare types of leukemia 2:06 p.m. Dec. 14, 2012 - MarketWatch.com

Cramer's Mad Money - Which IPOs To Watch, Which IPOs To Ignore (3/17/14) 6:15 a.m. Today - Seeking Alpha
Perilous Reversal Watch: Ariad Pharmaceuticals (ARIA) 3:03 p.m. March 17, 2014 - TheStreet.com
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog 10:58 a.m. March 5, 2014 - Zacks.com
ARIAD Pharmaceuticals' CEO Presents at Cowen and Company 34th Annual Health Care Conference (Transcript) 2:01 p.m. March 4, 2014 - Seeking Alpha
10-K: ARIAD PHARMACEUTICALS INC 5:15 p.m. March 3, 2014 - Edgar Online - (EDG = 10Q, 10K)
Ariad Pharmaceuticals (ARIA): Today's Pre-Market Leader Stock 8:19 a.m. Feb. 28, 2014 - TheStreet.com
Ariad on the move on Iclusig partnership chatter 3:45 p.m. Feb. 27, 2014 - Seeking Alpha
Should You Worry About the Short Interest in Ariad Pharmaceuticals (ARIA)? - Tale of the Tape 10:04 a.m. Feb. 27, 2014 - Zacks.com
Roundtable Top Picks for the Week of Feb. 24th - Video Blog 4:31 p.m. Feb. 26, 2014 - Zacks.com
ARIAD's Q4 Loss Narrower-Than-Expected - Analyst Blog 2:30 p.m. Feb. 26, 2014 - Zacks.com
Benzinga's Top Downgrades 7:23 a.m. Feb. 26, 2014 - benzinga.com
Ariad Pharmaceuticals' CEO Discusses Q4 2013 Results - Earnings Call Transcript 11:17 a.m. Feb. 25, 2014 - Seeking Alpha
Top Trending Tickers On StockTwits For February 25 10:12 a.m. Feb. 25, 2014 - benzinga.com
5 Biotech Stocks That Are Buyout Candidates 3:48 a.m. Feb. 25, 2014 - InvestorPlace.com
Earnings Scheduled For February 25, 2014 3:28 a.m. Feb. 25, 2014 - benzinga.com
Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Laggard 5:01 p.m. Feb. 24, 2014 - TheStreet.com
Ignyta: Now Public With A Targeted Oncology Pipeline Poised For Success 8:49 a.m. Feb. 24, 2014 - Seeking Alpha
Ariad gives activist investor a board seat, plans to add another 11:47 a.m. Feb. 21, 2014 - Seeking Alpha
Ariad Pharmaceuticals (ARIA) Strong In Pre-Market Trading 9:43 a.m. Feb. 21, 2014 - TheStreet.com
New positions from top healthcare stockpickers 3:51 p.m. Feb. 19, 2014 - Seeking Alpha

Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical 8:00 a.m. March 12, 2014 - PR Newswire - PRF
Most Active Equities Technical Snapshot: SandRidge Energy, Ariad Pharma, Groupon, and Vodafone 10:12 a.m. March 11, 2014 - PR Newswire - PRF
New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara 7:24 a.m. March 5, 2014 - PR Newswire - PRF
Workday Upgraded to $150 a Share; Ariad Pharmaceuticals Q4 Loss Widens 12:34 a.m. Feb. 28, 2014 - ACCESSWIRE
ARIAD Reports 2013 Financial Results and Outlines Key Objectives for 2014 7:35 a.m. Feb. 25, 2014 - BusinessWire - BZX
ARIAD to Present at the Cowen and Company 34th Annual Health Care Conference 7:35 a.m. Feb. 24, 2014 - BusinessWire - BZX
ARIAD Expands Its Board of Directors with Appointment of Alexander J. Denner, Ph.D. of Sarissa Capital Management 7:35 a.m. Feb. 21, 2014 - BusinessWire - BZX
Facebook to Buy Messaging App WhatsApp; Garmin Ltd. Hits New 1-year High on Earnings 12:29 a.m. Feb. 20, 2014 - ACCESSWIRE
ARIAD to Present at the RBC Capital Markets Healthcare Conference 7:35 a.m. Feb. 19, 2014 - BusinessWire - BZX
ARIAD to Host Conference Call and Webcast Discussion of Fourth Quarter and Year-End 2013 Financial Results on February 25, 2014 7:35 a.m. Feb. 10, 2014 - BusinessWire - BZX
TrendingWallStreet.com Announces Coverage on DDD, ARIA, ENIP, and LATF 12:24 a.m. Feb. 6, 2014 - ACCESSWIRE
ARIAD to Present at the Leerink Swann Global Healthcare Conference 7:35 a.m. Feb. 5, 2014 - BusinessWire - BZX
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Australia 7:35 a.m. Jan. 28, 2014 - BusinessWire - BZX
ARIAD Announces the Commercial Availability of Iclusig (Ponatinib) for Patients with Refractory Philadelphia-Positive Leukemias in the U.S. 7:35 a.m. Jan. 17, 2014 - BusinessWire - BZX
Divestiture, Service Deployment, Executive Promotion, Updated Outlook, and Designation Granted-Research Report on Endo, ARIAD, Align Technology, PAREXEL, and The Medicines Company 8:00 a.m. Jan. 16, 2014 - PR Newswire - PRF
ARIAD and Medinol Announce Initiation of Two Registration Trials of the NIRsupreme™ Ridaforolimus-Eluting Stent for Use in Coronary Artery Disease 7:35 a.m. Jan. 14, 2014 - BusinessWire - BZX
Biologics Selected by ARIAD to Be the Exclusive Specialty Pharmacy Provider for Iclusig (ponatinib) 7:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Notable Buzzers: Ariad Pharmaceuticals, Twitter Inc, Facebook Inc, Qihoo 360 Technology 11:10 a.m. Jan. 8, 2014 - ACCESSWIRE
Conferences, Completed Acquisitions, and Stock Price Movements - Research Report on Ariad, Salix, Molina, Mednax, and Merrimack 8:00 a.m. Jan. 7, 2014 - PR Newswire
Morning Buzzers: Apple Inc, Plug Power Inc, Ariad Pharmaceuticals, Biodel Inc 10:01 a.m. Jan. 3, 2014 - ACCESSWIRE

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...